Combination therapies prevent the neuropathic, proinflammatory characteristics of bone marrow in streptozotocin-induced diabetic rats.

Abstract

We previously showed that peripheral neuropathy of the bone marrow was associated with loss of circadian rhythmicity of stem/progenitor cell release into the circulation. Bone marrow neuropathy results in dramatic changes in hematopoiesis that lead to microvascular complications, inflammation, and reduced endothelial repair. This series of events represents early pathogenesis before development of diabetic retinopathy. In this study we characterized early alterations within the bone marrow of streptozotocin (STZ)-induced diabetic rats following treatments that prevent experimental peripheral neuropathy. We asked whether bone marrow neuropathy and the associated bone marrow pathology were reversed with treatments that prevent peripheral neuropathy. Three strategies were tested: inhibition of neutral endopeptidase, inhibition of aldose reductase plus lipoic acid supplementation, and insulin therapy with antioxidants. All strategies prevented loss of nerve conduction velocity resulting from STZ-induced diabetes and corrected the STZ-induced diabetes-associated increase of immunoreactivity of neuropeptide Y, tyrosine hydroxylase, and somatostatin. The treatments also reduced concentrations of interleukin-1β, granulocyte colony-stimulating factor, and matrix metalloproteinase 2 in STZ-induced diabetic bone marrow supernatant and decreased the expression of NADPH oxidase 2, nitric oxide synthase 2, and nuclear factor-κB1 mRNA in bone marrow progenitor cells. These therapies represent novel approaches to attenuate the diabetic phenotype within the bone marrow and may constitute an important therapeutic strategy for diabetic microvascular complications.

• Authors: James M Dominguez 2nd, Mark A Yorek, Maria B Grant
• Journal: Diabetes (Diabetes) Vol. 64 Issue 2 Pg. 643-53 (Feb 2015) ISSN: 1939-327X [Electronic] United States
• PMID: 25204979 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: © 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Chemical References

• AVE 7688
• Cytokines
• Fish Oils
• Heterocyclic Compounds, 3-Ring
• Hypoglycemic Agents
• Imidazolidines
• Insulin
• Membrane Glycoproteins
• Neuropeptide Y
• RNA, Messenger
• Menhaden oil
• Somatostatin
• Streptozocin
• Thioctic Acid
• fidarestat
• Nitric Oxide Synthase Type II
• Nos2 protein, rat
• Tyrosine 3-Monooxygenase
• Cybb protein, rat
• NADPH Oxidase 2
• NADPH Oxidases

Topics

• Adipose Tissue (physiology)
• Animals
• Bone Marrow (pathology)
• Cytokines (genetics, metabolism)
• Diabetes Mellitus, Experimental (therapy)
• Diabetic Neuropathies (prevention & control)
• Fish Oils (administration & dosage, therapeutic use)
• Gene Expression Regulation
• Heterocyclic Compounds, 3-Ring (administration & dosage, therapeutic use)
• Hypoglycemic Agents (administration & dosage, therapeutic use)
• Imidazolidines (therapeutic use)
• Inflammation (prevention & control)
• Insulin (administration & dosage, therapeutic use)
• Male
• Membrane Glycoproteins (genetics, metabolism)
• NADPH Oxidase 2
• NADPH Oxidases (genetics, metabolism)
• Neuropeptide Y
• Nitric Oxide Synthase Type II (genetics, metabolism)
• Pain Measurement
• RNA, Messenger (genetics, metabolism)
• Rats
• Rats, Sprague-Dawley
• Somatostatin
• Stem Cells
• Streptozocin
• Thioctic Acid (therapeutic use)
• Tyrosine 3-Monooxygenase